Fate Therapeutics Inc. (NASDAQ:FATE) insider Chris Storgard bought 37,593 shares of Fate Therapeutics stock in a transaction on Wednesday, November 23rd. The shares were bought at an average cost of $2.66 per share, with a total value of $99,997.38. Following the acquisition, the insider now directly owns 9,090 shares in the company, valued at $24,179.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Fate Therapeutics Inc. (NASDAQ:FATE) opened at 3.09 on Wednesday. Fate Therapeutics Inc. has a 12 month low of $1.46 and a 12 month high of $4.67. The company’s market cap is $105.52 million. The stock’s 50 day moving average price is $2.51 and its 200-day moving average price is $2.28.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. Fate Therapeutics had a negative return on equity of 112.48% and a negative net margin of 740.69%. Equities research analysts expect that Fate Therapeutics Inc. will post ($1.14) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Chris Storgard Buys 37,593 Shares of Fate Therapeutics Inc. (FATE) Stock” was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/30/chris-storgard-buys-37593-shares-of-fate-therapeutics-inc-fate-stock.html.

A number of research analysts have weighed in on FATE shares. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 11th. Roth Capital started coverage on Fate Therapeutics in a report on Thursday, September 22nd. They set a “buy” rating and a $8.00 target price for the company. Wedbush reduced their target price on Fate Therapeutics from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, November 8th. HC Wainwright reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, August 9th. Finally, BMO Capital Markets set a $4.00 target price on Fate Therapeutics and gave the company a “buy” rating in a report on Monday, August 8th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $5.79.

A number of institutional investors have recently added to or reduced their stakes in FATE. Northern Trust Corp boosted its position in Fate Therapeutics by 51.3% in the third quarter. Northern Trust Corp now owns 38,625 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 13,094 shares in the last quarter. Redmile Group LLC boosted its position in Fate Therapeutics by 1.0% in the second quarter. Redmile Group LLC now owns 1,502,180 shares of the biopharmaceutical company’s stock valued at $2,554,000 after buying an additional 15,200 shares in the last quarter. Lombard Odier Asset Management USA Corp boosted its position in Fate Therapeutics by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 256,426 shares of the biopharmaceutical company’s stock valued at $436,000 after buying an additional 7,052 shares in the last quarter. Board of Trustees of The Leland Stanford Junior University purchased a new position in Fate Therapeutics during the second quarter valued at $495,000. Finally, BlackRock Fund Advisors boosted its position in Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 15,701 shares in the last quarter. Institutional investors and hedge funds own 57.07% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

5 Day Chart for NASDAQ:FATE

Receive News & Stock Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related stocks with our FREE daily email newsletter.